Ventaris Surgical Secures $30M in Series A Funding
Ventaris Surgical, Inc., a medical device company known for its innovative approaches to kidney stone treatment, has successfully completed a $30 million Series A financing round. This financing is particularly significant as it aims to advance their next-generation ureteroscopic system designed to enhance kidney stone treatment outcomes.
Investment and Support
The financing round was led by Longitude Capital, which played a pivotal role in bringing additional support from other noteworthy investors. New participant Vensana Capital joined the ranks of existing supporters like Atypical Ventures, Neotribe Ventures, and Boutique Venture Partners. With this funding, Ventaris has welcomed Varun Gupta of Longitude Capital and Justin Klein of Vensana Capital to their Board of Directors, positioning the company for future growth.
Innovating Kidney Stone Procedures
At the heart of Ventaris Surgical's mission is a revolutionary ureteroscopic system aimed at achieving more effective stone clearance during kidney stone surgeries. These surgeries have become common procedures in urology, yet success often hinges on many factors, including surgeon skill and current tool limitations. With the technology being developed by Ventaris, there is hope for enhanced efficiency, possibly transforming how kidney stones are managed.
The CEO’s Vision
Surag Mantri, CEO of Ventaris Surgical, expressed his excitement about the potential impact of their technology, stating that while surgeons are committed to achieving complete stone clearance, the existing tools can often make this difficult. Ventaris was established with a clear intention: to minimize obstacles so that surgeons can concentrate on achieving optimal results. The support from Longitude Capital and Vensana is expected to drive significant advancements in this crucial medical area.
Future Steps with New Funding
The funds raised in this Series A financing round will be pivotal as Ventaris Surgical looks to continue its clinical development. These efforts will focus not only on refining the technology but also on moving through necessary regulatory pathways and reaching commercial milestones. This holistic approach will ensure that the innovative solutions Ventaris is developing not only reach the market but are also effective and safe for patient use.
About Ventaris Surgical
Ventaris Surgical, Inc. is a privately held company headquartered in San Carlos, CA. Its focus on medical device innovation is aimed at improving the surgical environment for urologists, specifically in treating kidney stones with a modern ureteroscopic system designed for greater stone clearance.
Frequently Asked Questions
What is Ventaris Surgical known for?
Ventaris Surgical is known for developing innovative medical devices specifically aimed at improving kidney stone treatment outcomes.
How much funding did Ventaris Surgical receive?
Ventaris Surgical announced a successful completion of a $30 million Series A financing round.
Who led the Series A financing?
The Series A financing was led by Longitude Capital, with additional participation from Vensana Capital and other existing investors.
What will the financing support?
Funding will support clinical development and efforts toward regulatory and commercial milestones for their ureteroscopic system.
Where is Ventaris Surgical located?
Ventaris Surgical is based in San Carlos, California, focusing on advancements in medical device technology.
